Randomized controlled trial of olanzapine or chlorpromazine as addition to lithium in the treatment of a first manic episode with psychotic features: an 8-week, flexible dose, single-blind trial

Détails

ID Serval
serval:BIB_61A18AA67168
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Titre
Randomized controlled trial of olanzapine or chlorpromazine as addition to lithium in the treatment of a first manic episode with psychotic features: an 8-week, flexible dose, single-blind trial
Titre de la conférence
Annual Conference of the Australasian-Society-for-Bipolar-Disorders
Auteur(s)
Conus P., Cotton S.U.E., Kader L., Macneil C.A., Hasty M., Hallam K.T., McGorry P.D., Berk M.
Adresse
Brisbane, Australia, OCT 22-24, 2009
ISBN
1398-5647
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
11
Série
Bipolar Disorders
Pages
779-779
Langue
anglais
Notes
Meeting Abstract
Résumé
Background: Association of mood stabiliser and antipsychotic medication is indicated in psychotic mania, but specific guidelines for the treatment of a first episode of psychotic mania are needed.
Aims: To compare safety and efficacy profiles of chlorpromazine and olanzapine augmentation of lithium treatment in a first episode of psychotic mania.
Methods: A total of 83 patients were randomised to either lithium + chlorpromazine or lithium + olanzapine in an 8-week trial. Data was collected on side effects, vital signs and weight modifications, as well as on clinical variables.
Results: There were no differences in the safety profiles of both medications, but patients in the olanzapine group were significantly more likely to have reached mania remission criteria after 8 weeks. Mixed effects models repeated measures analysis of variance showed that patients in the olanzapine group reached mania remission significantly earlier than those in the chlorpromazine group.
Conclusions: These results suggest that while olanzapine and chlorpromazine have a similar safety profile in a cohort of patients with first episode of psychotic mania, the former has a greater efficacy on manic symptoms. On this basis, it may be a better choice for such conditions.
Web of science
Création de la notice
04/11/2009 12:02
Dernière modification de la notice
20/08/2019 14:18
Données d'usage